BABYF
Else Nutrition Holdings Inc.·Consumer Defensive
0.14
7.692%(+0.01)
Close PriceLast Updated: — ET
52W L: $0.0152W H: $0.80
BABYF NEWS
prnewswire.com
Apr 15
Else Nutrition Commends Trump Administration's Expanded Commitment to Bolstering Infant Formulas Regulation in FY2027
President's Budget requested significant FDA funding increases, signaling growing support for Else's next-generation plant-based infant formula Builds Upon FY26 Congressional Appropriations Directive Report Language to Implement and Modernize Guidance for Plant-Based, Non-Soy, Non-Dairy Infant Formulas VANCOUVER, BC, April 15, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in whole-food plant-based, non-soy, non-dairy nutrition for early childhood and adult nutrition, today commended recent actions by the Trump Administration and the U.S. Food and Drug Administration (FDA) that signal increasing support for innovation and modernization within the infant formula market.
prnewswire.com
Mar 31
Else Nutrition Reports Fiscal Year 2025 Financial Results and Highlights Operational Progress, Strengthened Financial Foundation, and Clear Path Toward Profitability
/PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), today reported financial results for the 2025
defenseworld.net
Mar 23
Else Nutrn (OTCMKTS:BABYF) vs. Medtronic (NYSE:MDT) Financial Survey
Else Nutrn (OTCMKTS:BABYF - Get Free Report) and Medtronic (NYSE: MDT - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Earnings and Valuation This table compares Else Nutrn and
prnewswire.com
Mar 10
Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
Updated FDA Framework Bolsters Scientific Validation Pathway for Else's Plant‑Based Formula and Accelerates U.S. Commercialization Potential VANCOUVER, BC, March 10, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in whole-food plant-based, non-soy, non-dairy nutrition for early childhood nutrition, today announced that the U.S. Food and Drug Administration (FDA) has formally listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its Foods Program regulatory agenda.
